Introducing the science behind targeted treatments for non-small cell lung cancer and Immunotherapy: Virtual Study Day
Over the course of two mornings, experienced cancer educator, Dr Elaine Vickers, guides you through many of the most relevant topics relating to modern systemic treatments for non-small cell lung cancer (NSCLC).
Start: 10:00, 02 September 2020
End: 14:00, 03 September 2020
Event: Study day
The first morning’s focus is on the gene faults that drive many NSCLCs and on the targeted treatments that exploit these faults, such as inhibitors of EGFR, ALK, ROS1, B-Raf, HER2, MET and RET.
The second morning is about cancer’s relationship with the immune system and on the checkpoint inhibitor group of immunotherapies, which include PD-1, PD-L1 and CTLA-4 targeted antibody therapies.